| Jefferies LLC 520 Madison Avenue New York, NY 10022 |
SVB Leerink LLC 1301 Avenue of the Americas, 12th Floor New York, NY 10019 |
February 11, 2019
| Re: | Xeris Pharmaceuticals, Inc. Registration Statement on Form S-1 Registration File No. 333-229600 |
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Dear Sir/Madam:
Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933 (the “Act”), we, as representatives of the several Underwriters, wish to advise you that there will be distributed to each Underwriter or dealer, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934.
In accordance with Rule 461 of the Act, we hereby join in the request of Xeris Pharmaceuticals, Inc. for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:00 p.m. Eastern time on February 13, 2019, or as soon thereafter as practicable.
[Remainder of page intentionally left blank]
| Very truly yours, | ||
| By: | JEFFERIES LLC | |
| By: | /s/ Dustin Tyner | |
| Name: | Dustin Tyner | |
| Title: | Managing Director | |
| By: | SVB LEERINK LLC | |
| By: | /s/ Byron T. Webster | |
| Name: | Byron T. Webster | |
| Title: | Managing Director | |
[Signature page to Acceleration Request Letter]
-2-